Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Positive results for oral difelikefalin in Phase 2 nostalgia paresthetica study

By Brian Buntz | February 9, 2023

Cara TherapeuticsNEJM has published positive results from the KOMFORT Phase 2 trial of oral difelikefalin for nostalgia paresthetica, a condition involving itching, burning or tingly sensations on the back.

Cara Therapeutics (Nasdaq:CARA) is the developer of the drug, which won FDA approval in an injectable form for moderate-to-severe pruritus in hemodialysis patients in 2021. That form of the drug has the trade name Korsuva. Difelikefalin is a selective kappa-opioid receptor agonist.

The company’s stock dipped about 2% to $11.67 after the company announced the data.

Drug appeared effective but associated with adverse events

The KOMFORT study’s primary endpoint was a change in the weekly mean of the 24-hour Worst Itch Numeric Rating Scale (WI-NRS) score. At 8 weeks, more patients achieved an at least 4-point improvement with oral difelikefalin than with placebo.

The study recruited 126 patients total.

The NEJM article noted that, while the drug supported modest improvements in reducing itch intensity scores compared to the placebo, it was “associated with adverse events.”

Side effects resulted in 19% of participants in the difelikefalin group dropping out of the trial, compared to 6% of participants in the placebo group.

Secondary outcomes indicated improvements in sleep and itch-related quality of life.

Researchers at the Icahn School of Medicine at Mount Sinai conducted the research.

Future plans

Cara plans on conducting a Phase 2/3 study consisting of an 8-week Phase 2 dose-finding portion followed by two identical Phase 3 trials.

The company also has Phase 3 studies underway testing the potential of oral difelikefalin in advanced non-dialysis dependent chronic kidney disease and atopic dermatitis.

To date, there are no FDA-approved treatments for nostalgia paresthetica. Traditional treatments for the condition include topical creams and ointments, pain medications, transcutaneous electrical nerve stimulation (TENS) and physical therapy.

It is difficult to establish the incidence of nostalgia paresthetica, although many experts agree the condition is underdiagnosed. The condition is more common among women than in men, and usually affects people older than 40.


Filed Under: Dermatology
Tagged With: difelikefalin
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Takeda
TAK-279, an oral small-molecule TYK2 inhibitor offering the convenience of a once-daily pill and biologic-like clinical responses
AbbVie 770 logo
Upadacitinib shows promising results in ongoing phase 3 atopic dermatitis studies
plant under a microscope
Legacy Healthcare aims to upend alopecia areata treatment with a botanical drug
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE